224 related articles for article (PubMed ID: 33970849)
21. Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report.
Chouinard G; Bélanger MC; Beauclair L; Sultan S; Murphy BE
Prog Neuropsychopharmacol Biol Psychiatry; 1996 Aug; 20(6):1067-79. PubMed ID: 8888111
[TBL] [Abstract][Full Text] [Related]
22. Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice.
Sugimoto Y; Tagawa N; Kobayashi Y; Hotta Y; Yamada J
Biol Pharm Bull; 2007 Dec; 30(12):2399-401. PubMed ID: 18057733
[TBL] [Abstract][Full Text] [Related]
23. Increased serotonergic neurotransmission is not responsible for the anticompulsive effect of berberine in a murine model of obsessive-compulsive disorder.
Dixit PV; Parihar G; Jain DK; Jaiswal P
Behav Pharmacol; 2012 Oct; 23(7):716-21. PubMed ID: 22890212
[TBL] [Abstract][Full Text] [Related]
24. Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice.
Umathe SN; Manna SS; Jain NS
Behav Brain Res; 2011 Sep; 223(1):125-34. PubMed ID: 21549765
[TBL] [Abstract][Full Text] [Related]
25. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
Varigonda AL; Jakubovski E; Bloch MH
J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
[TBL] [Abstract][Full Text] [Related]
26. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Pigott TA; Seay SM
J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
[TBL] [Abstract][Full Text] [Related]
27. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
Todorov C; Freeston MH; Borgeat F
Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
[TBL] [Abstract][Full Text] [Related]
28. The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder.
Wald R; Dodman N; Shuster L
Exp Clin Psychopharmacol; 2009 Jun; 17(3):191-7. PubMed ID: 19586234
[TBL] [Abstract][Full Text] [Related]
29. Marble-burying behavior test as a murine model of compulsive-like behavior.
Dixit PV; Sahu R; Mishra DK
J Pharmacol Toxicol Methods; 2020; 102():106676. PubMed ID: 31954839
[TBL] [Abstract][Full Text] [Related]
30. Postpartum Lactation-Mediated Behavioral Outcomes and Drug Responses in a Spontaneous Mouse Model of Obsessive-Compulsive Disorder.
Mitra S; Mucha M; Owen S; Bult-Ito A
ACS Chem Neurosci; 2017 Dec; 8(12):2683-2697. PubMed ID: 28945961
[TBL] [Abstract][Full Text] [Related]
31. Animal models of obsessive-compulsive disorder.
Witkin JM
Curr Protoc Neurosci; 2008 Oct; Chapter 9():Unit 9.30. PubMed ID: 18972380
[TBL] [Abstract][Full Text] [Related]
32. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine.
Kampman M; Keijsers GP; Hoogduin CA; Verbraak MJ
Acta Psychiatr Scand; 2002 Oct; 106(4):314-9. PubMed ID: 12225499
[TBL] [Abstract][Full Text] [Related]
33. Psychopharmacology of comorbid obsessive-compulsive disorder and depression.
den Boer JA
J Clin Psychiatry; 1997; 58 Suppl 8():17-9. PubMed ID: 9236731
[TBL] [Abstract][Full Text] [Related]
34. Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine.
Egashira N; Harada S; Okuno R; Matsushita M; Nishimura R; Mishima K; Iwasaki K; Orito K; Fujiwara M
Eur J Pharmacol; 2007 Jun; 563(1-3):149-54. PubMed ID: 17349995
[TBL] [Abstract][Full Text] [Related]
35. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
Husted DS; Shapira NA; Murphy TK; Mann GD; Ward HE; Goodman WK
J Psychiatr Res; 2007; 41(3-4):332-7. PubMed ID: 16860338
[TBL] [Abstract][Full Text] [Related]
36. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
[TBL] [Abstract][Full Text] [Related]
37. Celecoxib potentiates the antianxiety and anticompulsive-like activity of fluoxetine against chronic unpredictable mild stress in experimental animals.
Garabadu D; Kumar V
Behav Pharmacol; 2019 Apr; 30(2 and 3-Spec Issue):251-259. PubMed ID: 30724800
[TBL] [Abstract][Full Text] [Related]
38. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder.
el Mansari M; Bouchard C; Blier P
Neuropsychopharmacology; 1995 Oct; 13(2):117-27. PubMed ID: 8597523
[TBL] [Abstract][Full Text] [Related]
39. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
[TBL] [Abstract][Full Text] [Related]
40. Combination of aripiprazole and ethanol attenuates marble-burying behavior in mice.
Gaikwad U; Parle M
Acta Pol Pharm; 2011; 68(3):435-40. PubMed ID: 21648199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
